NCT01068743View on ClinicalTrials.gov

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

saxagliptin

Tablets, Oral, 2.5 mg, once daily, single dose

DRUG

metformin

Tablets, Oral, 850 mg, once daily, single dose

DRUG

saxagliptin + metformin (FDC tablet)

Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors

Lead Sponsor

AstraZeneca
All Listed Sponsors
lead

AstraZeneca

INDUSTRY